Genetic Technologies Limited Announces Research Collaboration with Two World-Renowned Medical Centres
February 01 2019 - 5:30AM
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a
diversified molecular diagnostics company is pleased to announce
the execution of a 3-way Research Agreement between its subsidiary
Phenogen (100 % owned), Memorial Sloan Kettering Cancer Center
(MSK), New York and the University of Cambridge, UK. This
collaborative research study is to be led by Mark Robson, MD, Chief
of the Breast Medicine Service at MSK. The study is to assess
whether the provision of individual risk information informed by a
polygenic risk score (PRS) reduces decisional conflict among BRCA
mutation carriers considering preventive surgery.
Executive Chairman of GTG, Dr Paul Kasian
said, “the University of Cambridge has one of Europe’s leading
academic departments of population health sciences and cancer
genetic epidemiology. GTG is proud to be associated with these two
prestigious research institutes for this project.
This collaborative study provides two major
benefits for GTG:
(i) engagement and collaboration with high profile cancer
genetics researchers in the U.S.A. and Europe who are at the
forefront of risk assessment research; and
(ii) the resulting data has the potential to inform the design
of future pipeline products for GTG
The specific terms and conditions of the
Agreement are confidential but at a high level, GTG will supply
novel SNP-based genotyping for a clinical research study, through
its CLIA laboratory facility, Phenogen Sciences Inc, on a fee for
service basis.”
GTG will be responsible for the development and
validation of the new genetic assay, noting the fundamental
technology is similar to the existing GTG developed BREVAGenplus
breast cancer test and will fit synergistically into the Company’s
existing Melbourne-based laboratory infrastructure and processes.
Importantly, if the first phase of the study is successful, several
other major genetics centres in the U.S. have expressed an interest
in joining the study.
Dr Kasian said, “this Agreement represents
another milestone for GTG as it seeks to expand its genetic testing
product pipeline and become a key player in the genetic cancer risk
assessment landscape in Australia, the USA and in Asia”.
FOR FURTHER INFORMATION PLEASE CONTACT
Dr Paul
Kasian
Jason
Wong (USA)
Chairman and Acting CEO
Media and Investor
Relations
Genetic Technologies Limited
Blueprint Life Science Group
+61 3 8412
7000
+1 (415) 375 3340, Ext. 4
About Genetic Technologies
Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq:
GENE) is a diversified molecular diagnostics company. GTG offers
cancer predictive testing and assessment tools to help physicians
proactively manage patient health. The Company’s lead product,
BREVAGenplus®, is a clinically validated risk assessment test for
non-hereditary breast cancer and is first in its class. For
more information, please visit www.brevagenplus.com and
www.phenogensciences.com.
Genetic Technologies is developing a pipeline of
risk assessment products including a novel colorectal cancer (CRC)
test. For more information, please visit www.gtgcorporate.com
Safe Harbor StatementAny
statements in this press release that relate to the Company's
expectations are forward-looking statements, within the meaning of
the Private Securities Litigation Reform Act. The Private
Securities Litigation Reform Act of 1995 (PSLRA) implemented
several significant substantive changes affecting certain cases
brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC.
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024